ACTIVE Research Support
HPRC Seed Grant, Ganapathy (PI) Queimado (Mentor and Co-I)
08/01/2021-06/30/2023
TSET Health Promotion Research Center (HPRC)
Role of antioxidant and detoxification defense mechanisms in e-cigarettes induced oxidative stress
Specific aims of this project are: (1) to investigate if e-cigs impair NRFZ regulation of antioxidant, detoxification, and inflammatory responses in the lung cells; and (2) to determine whether sulforaphane can reverse e-cig induced oxidative stress and inflammation in mouse lungs.
R01CA242168, NIH/NCI, Queimado (PI)
07/01/2020-06/30/2025
National Institute of Health (NIH)/National Cancer Institute (NCI)
Biological impact of exclusive and dual e-cigarette use on oral cancer risk
Multi-Institutional study aiming: (1) to assess the genotoxic and mutagenic effects of e-cigs in exclusive and dual, e-cigs and combustible tobacco, users; (2) to characterize the impact of e-cigs use on oral mucosa transcriptome; and (3) to dissect the effect of e-cigs aerosol constituents on cellular genotoxicity and DNA repair capacity.
R23-02, Expansion Grant, Businelle (PI) Kendzor (PI) Queimado (HPRC Tobacco Regulatory Science Laboratory Director)
07/01/2019-Present
Tobacco Settlement Endowment Trust (TSET) Health Promotion Research Center (HPRC)
The purpose of this project is to establish the TSET Cancer Research Program to advance translational, clinical and population-based cancer research and serve to enhance efforts to prevent and combat cancer.
R01CA204891, NIH/NCI, Wagener (PI) Queimado (Site PI)
09/30/2016-08/31/2022
National Institutes of Health (NIH)/National Cancer Institute (NCI)
Examination of First and Second Generation E-cigarettes
Dr. Queimado is the PI in charge of Aim 3. Specific aims are: (1) to assess the effect of provision of G1 vs. G2 e-cigs on product switching/substitution, abuse liability, number of cigarettes smoked, and perceived nicotine dependence; (2) to evaluate changes in biomarkers of harmful tobacco constituent exposure among participants assigned to G1, G2, and UBC; and (3) to evaluate changes in biomarkers of toxicant effect among participants assigned to G1, G2, and UBC.
Clinical Trial, Jackson (PI) Queimado (Translational Studies, PI)
07/01/2016-Present
University of Oklahoma & Clovis Oncology, Inc.
A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Multi-Institutional study to determine whether the combination of rucaparib and bevacizumab will produce synergistic anti-cancer effect and increase progression-free survival (PFS) in patients with the carcinoma of the cervix or endometrium. The translational objective of this study is to determine whether the level of DNA damage in patient tumor biopsies is associated with response, PFS, and/or overall survival.
COMPLETED Research Support (past 2 years)
TSET Health Promotion Research Center, Queimado (PI) Gunderson (Co-PI)
11/18/2020-6/30/2022
Linking health risk factors, systemic DNA damage and cervical cancer risk
OSCTR Pilot Grant, Queimado (PI)
04/02/2020-06/30/2021
OSCTR/National Institutes of Health (NIH) IDeA Program
A new molecular tool to predict cervical cancer progression
R01CA196200, NIH/NCI, Benbrook (PI) Queimado (Co-I)
07/01/2015-06/30/2021
National Institutes of Health (NIH)/National Cancer Institute (NCI)
Ovarian Cancer Chemoprevention
HPRC Pilot Grant (Awarded, Declined), Tackett (PI) Queimado (Co-I)
01/01/2020-12/31/2020
TSET Health Promotion Research Center (HPRC)
The Acute Toxicological and Respiratory Profile of IQOS: A Preliminary Switch Trial
PHF Bridge Grant, Queimado (PI)
09/01/2019-06/30/2020
Presbyterian Health Foundation (PHF)
Biological impact of exclusive and dual e-cigarette use on oral cancer risk
R33CA202898, NIH/NCI, Queimado (PI)
04/08/2016-03/31/2020
National Institute of Health (NIH)/National Cancer Institute (NCI)
A Novel Molecular Assay for Early Detection and Assessment of Cancer Risk
Inventions/Patent
U.S. Patent Application 13/565,604: A Novel DNA Damage Detection Assay